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Abstract
Much work has been devoted to analysing thermodynamic models for solid disper-
sions with a view to identifying regions in the phase diagram where amorphous phase
separation or drug recrystallization can occur. However, detailed partial differential equa-
tion non-equilibrium models that track the evolution of solid dispersions in time and
space are lacking. Hence theoretical predictions for the timescale over which phase sep-
aration occurs in a solid dispersion are not available. In this paper, we address some
of these deficiencies by (i) constructing a general multicomponent diffusion model for a
dissolving solid dispersion; (ii) specializing the model to a binary drug/polymer system
in storage; (iii) deriving an effective concentration dependent drug diffusion coefficient
for the binary system, thereby obtaining a theoretical prediction for the timescale over
which phase separation occurs; and (iv) presenting a detailed numerical investigation of
the HPMCAS/Felodipine system assuming a Flory-Huggins activity coefficient. The nu-
merical simulations exhibit numerous interesting phenomena, such as the formation of
polymer droplets and strings, Ostwald ripening/coarsening, phase inversion, and droplet-
to-string transitions.
Keywords: amorphous solid dispersion, phase separation, mathematical model, drug diffusion
1 Introduction
Drugs that are delivered orally via a tablet should ideally be readily soluble in water. Drugs
that are poorly water-soluble tend to pass through the gastrointestinal tract before they can
fully dissolve, and this typically leads to poor bioavailability of the drug. Unfortunately, many
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drugs currently on the market or in development are poorly water-soluble, and this presents
a serious challenge to the pharmaceutical industry. Many strategies have been developed to
improve the solubility of drugs, such as the use of surfactants, cocrystals, lipid-based formu-
lations, and particle size reduction. The literature on this topic is extensive, and recent reviews
can be found in [31, 38, 22].
One particularly effective strategy to improve drug solubility is to use a solid dispersion
[5, 20, 10]. A solid dispersion typically consists of a hydrophobic drug embedded in a hy-
drophilic polymer [35, 16] matrix, where the matrix can be either in the amorphous or crys-
talline state. The drug is preferably in a molecularly dispersed state, but may also be present
in amorphous particles or even in the crystalline form (though this is usually undesirable); see
Figure 1. The drug release concept for most solid dispersions is based on the so-called spring
and parachute effect [6]. When the drug and the hydrophilic polymer dissolve in solution, a
supersaturated drug solution is quickly created (the spring). Although the drug concentration
then subsequently decreases, the rate of decrease is slowed by drug-polymer interactions in
the dispersion, so that the drug can be present at supersaturated levels in the solution for a pe-
riod of some hours (the parachute). This results in improved bioavailability of the drug when
the solid dispersion dosage form is taken orally.
Molecularly dispersed
drug in the polymer
matrix (desirable)
Drug molecule
Polymer matrix
Crystal drug formation
has occurred (undesirable)
Contains amorphous
drug-rich domains
Figure 1: Adapted from [20]. In this figure, we show three possible structures for a poly-
mer/drug dispersion. Top: Here the drug is in the molecularly dispersed state, which is usu-
ally desirable for a solid dispersion. Bottom left: Here the dispersion contains drug in the
crystalline form. Bottom right: Here the dispersion contains amorphous drug-rich domains.
Drug loading in most dispersions greatly exceeds the equilibrium solubility in the polymer
matrix for typical storage temperatures. Hence these systems are usually unstable, with phase
separation eventually occurring [20]. In such cases, the drug will eventually crystallise out or
form an amorphous phase separation. However, if the dispersion is stored well below the glass
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transition temperature [12] for the polymer, and is kept dry, this can happen extremely slowly.
The system is then for all practical purposes stable, and is said to be metastable. The humidity
of the storage environment can be an issue because even small amounts of moisture can signif-
icantly affect the glass transition temperature. Hence polymers that have high glass transition
temperatures and that are resistant to water absorption have become popular. An example of
one such polymer is Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS).
Phase separation of solid dispersions in storage is clearly undesirable from the point of
manufacturers. Hence much work has been devoted to constructing phase diagrams for solid
dispersions with a view to identifying regimes where drug recrystallization or amorphous
phase separation can occur. These phase diagrams are constructed with the aid of thermo-
dynamic models. The most widely used thermodynamic model in this context is the Flory-
Huggins model [15, 21, 18] for polymer solutions.
Flory-Huggins theory is a lattice-based model in which the drug and polymer are confined
to live on a regular lattice. Flory-Huggins theory is an extension of regular solution theory, as
explained in Chapter 7 of [18]. In the context of a drug/polymer system, each drug molecule
is taken to occupy one lattice site and each polymer segment is taken to occupy m 1 sites.
Under a number of further simplifying assumptions [18], the change in entropy and enthalpy
associated with the mixing of the polymer and drug are calculated. With these in hand, the
change in Gibbs free energy (∆Gmix) per mole associated with mixing is readily calculated,
and is found to be
∆Gmix
RT
= Xd ln(φd) +Xp ln(φp) + χdpXdφp, (1)
where R is the gas constant, T is the temperature, Xd, Xp = 1−Xd are the mole fractions of
the drug and polymer, respectively, and φd, φp are the volume fractions of the drug and poly-
mer, respectively. The quantity χdp is referred to as the Flory-Huggins interaction parameter,
and it is discussed further below. The mole fractions and volume fractions are related via the
formulae
φd =
Xd
Xd +mXp
, φp =
mXp
Xd +mXp
. (2)
When the model is applied to real binary systems, m can be calculated using the formula
m =
Vp
Vd
(3)
where Vp, Vd (molar−1) are the molar volumes of the polymer and drug, respectively.
The mixing of the polymer and drug is spontaneous if ∆Gmix < 0. The Flory-Huggins
parameter χdp takes the form
χdp = ρ
2
(
wdp − wdd + wpp
2
)
(4)
where ρ2 is a positive parameter, and wdp, wdd, wpp give measures of the drug-polymer, drug-
drug and polymer-polymer interaction energy, respectively. If χdp < 0 then wdp < (wdd +
wpp)/2 indicating that that the mixed state has lower energy than the separated pure states,
so that mixing is favoured. Conversely, χdp > 0 is indicative of demixing being favoured.
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However, these statements are indicative rather than precise, as will be explained in Section
3. We should also note that χdp is temperature dependent, and is usually given the empirical
form
χdp(T ) =
α
T
+ β (5)
where α, β are constants.
Flory-Huggins theory has frequently been used to analyse the stability of binary solid
dispersion systems in storage; see, for example, [11, 37, 36, 4, 9, 1, 8, 24, 39, 40]. In many
of these studies, the Flory-Huggins interaction parameter is first estimated using the melting
point depression method [25], or using the Hildebrand and Scott method [19], which involves
the estimation of solubility parameters. Once estimates for χdp(T ) have been obtained, the
Gibbs free energy of mixing ∆Gmix can be calculated, which in turn enables the construction
of phase diagrams for the systems. Phase diagrams assist with the identification of regions in
composition-temperature space where the system is prone to recrystallization or amorphous
phase separation.
The models we shall develop in the current study are generic and are not tied to making
a specific choice of statistical model. However, given the particular importance of Flory-
Huggins theory in applications, we shall derive detailed results for this case. Also, all of our
numerical illustrations are calculated within the context of Flory-Huggins theory. It should be
emphasized that Flory-Huggins theory does involve quite a number of simplifying assump-
tions which are not appropriate for some systems; see [2] for a recent critique of the model.
2 Theoretical formulation
2.1 A multicomponent diffusion model for solid dispersions
We develop a multicomponent diffusion model for the evolution of the concentrations of the
components constituting a solid dispersion. We suppose for the moment that there are p
components. However, in the analysis we shall consider in the current study, we will in fact
have p = 2, with one of the components being the polymer, and the other being the drug. For
a dissolving solid dispersion, there are three components p = 3: the polymer, the drug, and
the solvent.
The chemical potential µi (J/mole) of species i (i = 1, 2, ..., p) gives the Gibbs free energy
per mole of species i, and is given here by ([34])
µi = µ
b
i − 2i∇2Xi (6)
where
µbi = µ
0
i +RT ln(ai) (7)
and where µbi is the bulk chemical potential of species i, µi0 is the chemical potential of
species i in the pure state, ai is the activity of species i, and the term involving 2i > 0
(m2J/mole) penalises the formation of phase boundaries ([33],[32]). The parameters 2i are
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referred to as gradient energy coefficients ([7], [14]). Here Xi is the molar fraction of species
i (i = 1, 2, ..., p), and the activities can depend on these molar fractions, so that
ai = ai(X1, X2, ..., Xp).
The molar fraction is related to the molar concentration via
Xi = Vici (8)
where Vi (molar−1) is the molar volume of species i. The flux of species i (molar·m/s) is given
by
Ji = civi (9)
where ci (molar), vi (m/s) give the molar concentration and drift velocity, respectively, of
species i. The drift velocity vi gives the average velocity a particle of species i attains due to
the diffusion force acting on it, and is given here by
vi = MiFi = −Mi∇µi (10)
where Mi (mole·s/kg), Fi (J/[m·mole]) give the mobility and diffusion force, respectively, for
species i. Equations (9) and (10) give
Ji = −Mici∇µi. (11)
Conservation of mass for species i implies that
∂ci
∂t
+∇ · Ji = 0 (12)
and using (11) now gives
∂ci
∂t
= ∇ · (Mici∇µi)
or equivalently
∂Xi
∂t
= ∇ ·
(
DiXi∇
{
µi − µi0
RT
})
(13)
with
µi − µi0
RT
= ln(ai)− δ2i∇2Xi (14)
for i = 1, 2, ..., p, and where δ2i = 
2
i /RT > 0 (m
2/molar), and
Di = MiRT (Einstein relation)
is the self-diffusion coefficient for species i.
The model formulation given by (13) and (14) based on chemical potentials will be used
for the numerical scheme described in Section 4. However, it is also of value to develop a
formulation involving diffusion coefficients since these yield immediate information regard-
ing timescales for transport processes, and will also the enable the development of analytical
results via a linearization process.
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Diffusion Coefficients
Using (6), (7) and (11) gives
Ji = −Mici∇µi = −Mici
(
RT
ai
∇ai − 2i∇(∇2Xi)
)
and then using the fact that the activities depend on the molar fractions gives
Ji = −Mici
(
RT
ai
p∑
j=1
∂ai
∂Xj
∇Xj − 2i∇(∇2Xi)
)
. (15)
Using (8), we can now write (15) as
Ji = −
p∑
j=1
Dij∇cj +Diε2i ci∇(∇2ci) (16)
where ε2i = Viδ
2
i and where the diffusion coefficients Dij (m
2/s) are given by
Dij = Di
Vj
Vi
Xi
ai
∂ai
∂Xj
. i, j = 1, 2, ..., p (17)
Conservation of mass (12) then implies that (reverting to molar fractions)
∂Xi
∂t
= ∇ ·
(
p∑
j=1
Vi
Vj
Dij(X)∇Xj −Diδ2iXi∇(∇2Xi)
)
i = 1, 2, ..., p (18)
where X = (X1, X2, ..., Xp), and where we have included the concentration dependence of
the diffusion coefficientsDij here to emphasise that this system is in general a coupled system
of nonlinear diffusion equations. It should benoted that the equations (18) are not independent
since
∑p
i=1Xi = 1, and so it is sufficient to solve for p− 1 concentrations only.
2.2 Activity coefficients
The activities ai are usually written as
ai = γiXi
where the γi = γi(X1, X2, ..., Xp) are referred to as activity coefficients. Equations (17) now
give
Dij = Di
Vj
Vi
(
δij +
Xi
γi
∂γi
∂Xj
)
i, j = 1, 2, ..., p (19)
where δij is the Kronecker delta.
The details of the interactions between the species in solution are captured in the mod-
elling by choosing appropriate forms for the activity coefficients γi = γi(X1, X2, ..., Xp). The
construction of appropriate forms for the γi for various solutions is a large subject with a large
literature; see, for example, the books [23] and [29].
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2.3 The storage problem for a binary mixture
In the current study, we shall be modelling the behaviour of solid dispersions in storage. In
this case, we have p = 2, with the label 1 referring to the drug and the label 2 referring to
the polymer. However, for transparency, we choose here to use the labels d, p rather than 1, 2,
where d stands for drug, and p for polymer. Then using (18) and the fact that Xp = 1 −Xd,
we have
∂Xd
∂t
= ∇ · {Deff(Xd)∇Xd −Ddδ2dXd∇ (∇2Xd)} . (20)
where the effective concentration-dependent diffusion coefficient for the drug in the solid
dispersion is
Deff(Xd) = Ddd(Xd)− VdDdp(Xd)/Vp = Dd
{
1 +
Xd
γd
[
∂γd
∂Xd
− ∂γd
∂Xp
]}
. (21)
For the particular case of a binary Flory-Huggins theory (see Section 1), the activity coeffi-
cients are given by
ln(γd) = ln
(
φd
Xd
)
+ 1− φd
Xd
+ χdpφ
2
p, (22)
ln(γp) = ln
(
φp
Xp
)
+ 1− φp
Xp
+mχdpφ
2
d, (23)
where the volume fractions φd, φp are given by (2). Substituting (22) in (21) gives
Deff(Xd) = Dd
{
(m− (m− 1)Xd)(m2 − (m2 − 1)Xd)− 2χdpm2Xd(1−Xd)
(m− (m− 1)Xd)3
}
. (24)
It is more instructive to write this expression in terms of the volume fraction of drug. Writing
Deff(Xd) = D˜eff(φd), we obtain
D˜eff(φd) = Dd(1 + (m− 1)φd)
(
1 +
(
1
m
− 1
)
φd − 2χdpφd(1− φd)
)
. (25)
This expression is particularly useful because it yields insight into how the mobility of the drug
in the dispersion depends on the length of the polymer chains (m), the dispersion composition
(φd), and the character of the drug-polymer interaction (χdp). We shall analyze this expression
further in Section 3, and also show how it can be used to calculate the timescale over which
phase separation may occur.
An equivalent formulation for the Flory-Huggins model involving the chemical potential
for the drug µd is given by (see (13) and (14) above):
∂Xd
∂t
= ∇ · (DdXd∇ψ) (26)
where
ψ =
µd − µd0
RT
(27)
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and with
ψ = ln
(
Xd
m− (m− 1)Xd
)
+
(m− 1)(1−Xd)
m− (m− 1)Xd + χdpm
2
(
1−Xd
m− (m− 1)Xd
)2
− δ2d∇2Xd.
(28)
We suppose that the solid dispersion occupies a two-dimensional region Ω. The governing
equation for the drug concentration in Ω may be written in the conservation form
∂Xd
∂t
+∇ · Jd = 0,
where the drug flux Jd is given by
Jd = −Deff(Xd)∇Xd +Ddδ2dXd∇(∇2Xd). (29)
We need to supplement the governing equation in Ω with boundary conditions on ∂Ω, and we
choose these here to be
∇Xd · n = 0, ∇(∇2Xd) · n = 0 on ∂Ω. (30)
We note from (29) that the choice of boundary conditions (30) implies that
Jd · n = 0 on ∂Ω,
so that there is no flux of drug through the boundary. Finally, to obtain a well-posed problem,
we need to impose an initial condition and we choose this here to take the form
Xd(x, y, t = 0) = X
0
d(x, y) for (x, y) ∈ Ω, (31)
where X0d(x, y) is a given function.
Gathering together the governing equation, the boundary conditions and the initial condi-
tion, we obtain the following initial boundary value problem:
∂Xd
∂t
= ∇ · {Deff(Xd)∇Xd −Ddδ2dXd∇ (∇2Xd)} in Ω,
∇Xd · n = 0, ∇(∇2Xd) · n = 0 on ∂Ω, (32)
Xd(x, y, t = 0) = X
0
d(x, y) for (x, y) ∈ Ω.
2.4 Phase separation in a Flory-Huggins binary mixture
The bulk free energy and spinodal decomposition
Spinodal decomposition for binary systems has been long understood using thermody-
namic reasoning, and is well described elsewhere; see, for example, Chapter 5 of [28], Chap-
ter 7 of [18], or [13]. Hence our description of the background theory here will be quite brief,
and we will emphasise instead the particular details for the Flory-Huggins system.
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The bulk free energy density gb for the binary mixture constituting the solid dispersion is
given by ([3])
gb = µ
b
dXd + µ
b
pXp, (33)
where µbd, µ
b
p give the bulk chemical potential of the drug and polymer, respectively, and where
µbi = µ
0
i +RT ln(ai) for i = d, p.
This leads to
gb = µ
0
dXd + µ
0
pXp +RT (Xd ln(Xd) +Xp ln(Xp)) +RT (Xd ln(γd) +Xp ln(γp)).
If we now use (22) and (23) and the fact that Xp = 1−Xd, we arrive at
gb = µ
0
p + (µ
0
d − µ0p)Xd +RT
{
Xd ln
(
Xd
m− (m− 1)Xd
)
+(1−Xd) ln
(
m(1−Xd)
m− (m− 1)Xd
)
+
χdpmXd(1−Xd)
m− (m− 1)Xd
}
. (34)
In Figure 2 (a), we plot a free energy density diagram gb as a function of drug molar fraction
Figure 2: (a) Plot of the bulk free energy density gb as a function of a drug molar fraction
Xd. The spinodal points X1sd , X
2s
d are the solutions to d
2gb/dX
2
d = 0. In the spinodal region
(X1sd , X
2s
d ), we have d
2gb/dX
2
d < 0 and Deff(Xd) < 0. (b) Phase diagram for the binary
mixture. Here α is the coexistence curve, β is the spinodal curve, T ∗ is the temperature for
the free energy density diagram in (a), and Tc is the critical temperature above which the
dispersion is homogeneous.
Xd. In this diagram, the points X1sd , X
2s
d are the solutions to
d2gb
dX2d
= 0,
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and are referred to as the spinodal points. The region (X1sd , X
2s
d ) is referred as the spinodal
region, and for points Xd in this region, we have
d2gb
dX2d
< 0.
Compositions Xd in the spinodal region are unstable, and will split into two phases character-
ized by the compositionsX1ud andX
2u
d as shown in Figure 2 (a); see [28] for more details. The
points X1ud , X
2u
d are referred to as the binodal points, and are defined by the common tangent
construction shown in Figure 2 (a). The binodal and spinodal points define the coexistence
and spinodal curves, respectively, and these are plotted in the phase diagram shown in Figure
2 (b).
Using equation (34), we obtain
d2gb
dX2d
= RT
q(Xd)
(1− (1− 1/m)Xd)3Xd(1−Xd) (35)
where
q(Xd) = AX
2
d +BXd + 1 (36)
and where
A =
1
m3
− 1
m2
− (1− 2χdp) 1
m
+ 1, B =
1
m2
+ (1− 2χdp) 1
m
− 2. (37)
Hence there is a spinodal region with d2gb/dX2d < 0 if q(Xd) < 0 in this region. Inspecting
(36), we see that q(Xd) can be negative if q(Xd) = 0 has real roots, that is, if
B2 − 4A > 0,
and using (37), this leads to
(2χdp − (1 + 1/m))2 − 4/m > 0
which holds true if
χdp >
1
2
(
1 +
1√
m
)2
=
1
2
(
1 +
√
Vd/Vp
)2
.
Hence, we have a spinodal interval if
χdp > χ
c
dp(m) (38)
where
χcdp(m) ≡
1
2
(
1 +
1√
m
)2
, (39)
and where χcdp(m) is a critical value for the Flory-Huggins parameter. If (38) holds true, then
there is a spinodal interval (X1sd , X
1s
d ) ⊂ [0, 1] where
X1sd =
−B −√B2 − 4A
2A
, X2sd =
−B +√B2 − 4A
2A
, (40)
10
and where A, B are given in (37).
The diffusion coefficient and spinodal decomposition
Using (25) and (35), elementary calculations show that
Deff(Xd) = M
†(Xd)
d2gb
dX2d
(41)
where
M †(Xd) = MdXd(1−Xd)
with Md = Dd/RT , and where M †(Xd) is a concentration-dependent drug mobility; see, for
example, equation (3.6) of the paper [27]. Hence, for 0 < Nd < 1, it is clear from (41) that
d2gb/dX
2
d < 0 implies that
Deff(Xd) < 0. (42)
Hence, an equivalent criterion for spinodal decomposition to occur is that there exist a region
in 0 ≤ Xd ≤ 1 where Deff(Xd) < 0, that is, that there exist a region where drug diffusion is
against the concentration gradient (uphill diffusion).
Figure 3: Plots of the scaled effective diffusion coefficient for the drug in the polymer disper-
sion as a function of the drug volume fraction. Here positive values of the diffusion coefficient
correspond to standard drug diffusion down the concentration gradient, while negative values
correspond to phase separation of the drug and the polymer, with larger negative values (in
absolute terms) corresponding to more rapid phase separation. We have plotted the scaled
drug diffusion coefficient for (a) the Flory-Huggins interaction parameter χdp = 3 and various
values of the polymer chain length m, and, (b) polymer chain length m = 50 and various val-
ues of the Flory-Huggins interaction parameter χdp. See the main body of the text for further
discussion.
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3 Qualitative results and discussion
Although the model we have derived in the current study is quite general, and is not tied to
any specific statistical model for a solid dispersion, the detailed results we shall present in this
section are for the Flory-Huggins case.
3.1 The effective diffusion coefficient for the drug in the dispersion
From (25), the scaled effective diffusion coefficient for the drug in the dispersion is given by
D˜eff(φd)
Dd
= (1 + (m− 1)φd)
(
1 +
(
1
m
− 1
)
φd − 2χdpφd(1− φd)
)
(43)
where we recall that Dd is the temperature-dependent self-diffusion coefficient for the drug.
Equation (43) is of particular value since it yields information on how the mobility of the drug
in the dispersion depends on the polymer chain length, the dispersion composition, and the
character of the drug-polymer interaction.
In Figure 3 (a), we have plotted (43) for the Flory-Huggins interaction parameter χdp = 3
(which is in the unstable regime) and various values of the polymer chain length m. It should
be emphasized that positive values for D˜eff correspond to standard drug diffusion down the
concentration gradient, while negative values correspond to unstable regimes where phase
separation of the drug and polymer can occur. In Figure 3 (a), it is clear that if the drug
loading φd is sufficiently low, then D˜eff > 0 and the solid dispersion is stable. However, for
larger (and more realistic) drug loadings, D˜eff < 0, and the system is unstable. It is interesting
to note that the system becomes more unstable as the length of the polymer chains increase.
It is also clear from the curves in Figure 3 (a) that the relationship between the initial drug
loading in the dispersion and the initial rate of phase separation is not altogether obvious.
It is not necessarily the case that increasing drug loading corresponds to increasing initial
dispersion instability. Rather, there is in fact a well defined worst choice for the initial drug
loading from the point of view of stability in the initial stages. This worst choice corresponds
to the minima of the curves displayed in Figure 3 (a), since these minima correspond to the
fastest rates of phase separation. For m 1, the minimum of D˜eff(φd) occurs at
φmind ≈
1 + 2χdp +
√
(1 + 2χdp)2 − 6χdp
6χdp
. (44)
These theoretical results predict that choosing initial drug loadings φd above or below φmind
should lead to improved dispersion stability in the initial stages. For m,χdp  1, we have
φmind ≈ 0.67.
In Figure 3 (b), we plot (43) for the fixed polymer lengthm = 50, and various values of the
Flory-Huggins interaction parameter χdp. For m = 50, the critical value for χdp is given by
χcdp ≈ 0.5707 (see equation (39)). Recall that for χdp < χcdp, the system is stable for all drug
loadings φd, and that for χdp > χcdp, there is a regime of unstable drug loadings. This is borne
out by the curves displayed in Figure 3 (b). These curves predict that the system becomes
more unstable with increasing values of χdp, and this is as expected given the dependence of
χdp on the interaction energies - see equation (4).
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Figure 4: Schematic of a phase separating solid dispersion where polymer-rich regions with
characteristic lengthscale l have formed. A formula for the timescale of evolution of such a
dispersion is given in the main body of the text; see equation (45).
3.2 Timescale for phase separation in a solid dispersion
In Figure 4, we give a schematic of a phase separating solid dispersion where polymer-rich
regions have formed. The characteristic lengthscale of these regions is denoted by l. In order
for such regions to form, the drug must have diffused away over a lengthscale of order l, and
the timescale over which this diffusion occurs is estimated by (see (25))
τ =
l2
|D˜eff(φ0d)|
=
l2
Dd(T )
1
|(1 + (m− 1)φ0d)[1 + (1/m− 1)φ0d − 2χdp(T )φ0d(1− φ0d)]|
(45)
where φ0d is the initial uniform volume fraction of the drug in the dispersion, and T is a rep-
resentative storage temperature. It should be emphasized that this formula is just an estimate
since, in reality, the drug volume fraction evolves in space and time. Hence, (45) should only
be used as a rough rule of thumb. In Section 4, we evaluate this formula by comparing it with
detailed numerical results, and satisfactory agreement is generally found.
Equation (45) may, in appropriate circumstances, be used to estimate the shelf life of a
solid dispersion product. To see this, suppose that l denotes the largest acceptable size for
polymer-rich domains (or drug-rich domains) in the product. Then, since τ estimates the
timescale for these regions to form, it also estimates the timescale for the shelf life of the
product. However, care should be taken when using (45) since, apart from the fact that is
based on a fixed value of φd, it also incorporates a number of significant assumptions - for
example, it assumes that the dispersion is perfectly dry, and that Flory-Huggins theory is an
appropriate statistical model for the system.
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3.3 Criteria for a stable solid dispersion
Although the drug loading in real solid dispersions is typically high and in the unstable regime,
it is nevertheless worthwhile specifying conditions under which the stability of the dispersion
is guaranteed. The results we display here are based on the discussion given in Section 2.4.
For χdp < χcdp where χ
c
dp =
1
2
(1 + 1/
√
m)
2, the system is stable irrespective of the choice of
the uniform initial drug load φ0d. For χdp > χ
c
dp, the dispersion is unstable if the initial drug
loading φ0d is chosen in the interval (φ
−
d , φ
+
d ), but stable if chosen in either of the intervals
(0, φ−d ) or (φ
+
d , 1), where
φ±d =
1
2
1 + 12χdp
(
1− 1
m
)
±
√[
1 +
1
2χdp
(
1− 1
m
)]2
− 2
χdp
 .
These results are based on the bulk free energy only, and do not take account of interfacial
energy.
4 Numerical results and discussion
4.1 The numerical method
For the purposes of numerical calculations, we take the integration domain to be the square
region Ω = {(x, y)| 0 < x < L, 0 < y < L} with boundary ∂Ω. The governing equation to
be solved is defined by the equations (26), (27) and (28). The boundary conditions are given
by
∇ψ · n = 0 and ∇Xd · n = 0 on ∂Ω,
and the initial condition takes the form (31). The governing equation was numerically inte-
grated using the finite element package COMSOL Multiphysics, employing a triangular mesh
consisting of 7553 vertices and 14796 triangles. The numerical solutions all conserved the
total mass of drug in the system to good accuracy, as required. Also, different meshes were
experimented with to ensure that the numerical solutions were grid independent.
4.2 Parameter values
We consider parameter values that are appropriate for a solid dispersion consisting of the
drug Felodipine (FD) and the polymeric excipient HPMCAS. Felodipine is a calcium channel
blocker that is commonly used to treat blood pressure. For this system, the Flory-Huggins
interaction parameter is given as a function of temperature by (see [37])
χdp(T ) = −18.767 + 7830.4
T
. (46)
Using data taken from [37], the molar volume for FD is Vd = 300.19 cm3/mol and the molar
volume of HPMCAS is Vp = 14007.78 cm3/mol, so that
m =
Vp
Vd
=
14007.78
300.19
≈ 46.6630.
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T (oC) χdp(T ) Dd(T ) (m2s−1) Deff(Xa) (m2s−1)
40 6.2383 1.1661× 10−18 8.8605× 10−17
50 5.4645 1.5494× 10−17 1.0113× 10−15
60 4.7371 1.3787× 10−16 7.6107× 10−15
75 3.7245 2.0297× 10−15 8.3587× 10−14
90 2.7954 1.7356× 10−14 4.9151× 10−13
100 2.2176 5.7436× 10−14 1.1670× 10−12
110 1.6699 1.6336× 10−13 2.0806× 10−12
120 1.1501 4.0902× 10−13 2.2657× 10−12
Table 1: Illustrative values for some of the parameters of the FD/HPMCAS system at various
temperatures. Here the initial weight fraction of drug is 70%, which corresponds to an initial
drug molar fraction Xd ≈ 0.9909.
From (39), the critical value for the interaction parameter below which phase separation can-
not occur is given by
χcdp(m) =
1
2
(
1 +
1√
m
)2
= 0.6571.
The self-diffusion coefficient for Felodipine was estimated in [17] (Chapter 4, page 133) to be
Dd(T ) = exp(−A1) exp
(
−A2
T
exp
(
A3
T
))
m2s−1 (47)
where A1 = 18.03, A2 = 445.84 K, A3 = 874.81 K. Some illustrative values for the diffusion
coefficients and the Flory-Huggins interaction parameter are displayed in Table 1.
For the numerical simulations displayed in the current study, we take the size of the square
domain to be given by L = 2 mm. The thickness of the interfacial regions is dictated by the
parameter δd, and here we chose the value δd = L/50 = 4 × 10−5 m. We illustrate how the
initial conditions were specified by considering a particular case. We consider the case where
the initial weight fraction of drug is 80%. This means that the initial weight of FD divided
by the weight of FD plus the weight of HPMCAS is 0.8. This corresponds to an initial molar
drug fraction of Xd = 0.9947. More precisely, we choose the initial molar fraction of drug to
be a small random perturbation about this level given by
Xd(x, y, t = 0) = 0.9947(1 + rnd(x, y))
where rnd(x, y) is a normally distributed random function with a mean value of zero and a
standard deviation of 10−5.
4.3 Numerical results
The results of the numerical simulations are displayed in Figures 5, 6, 7, 8, and these cor-
respond to weight fractions of drug of 80%, 60%, 40% and 20%, respectively. Recall that
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T = 60◦C T = 90◦C T = 120◦C
1 day 1 hour 0.5 hours
2 days 3 hours 1 hour
1 week 4 hours 1 day
1 month 1 day 1 week
6 months 1 week 2 months
Figure 5: Simulations of a FD/HPMCAS solid dispersion obtained by numerically integrating
the initial boudary value problem defined in Section 4.1. The colours correspond to different
mole fractions of the drug as defined by the colour bar. The weight fraction of drug here
is 80%, and the other parameter values can be found in Section 4.2. In the above frame of
figures, each column corresponds to a different temperature, and reading a column from top
to bottom corresponds to increasing time for the dispersion for the given temperature.
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T = 60◦C T = 90◦C T = 120◦C
1 day 0.5 hours 1.5 hours
1 week 1 hour 1 day
1 month 1 day 1 week
6 months 1 week 1 month
1 year 1 month 9 months
Figure 6: See the caption for Figure 5. The weight fraction of drug here is 60%.
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T = 60◦C T = 90◦ C T = 110◦C
1 week 3 hours 3 hours
2 weeks 6 hours 6 hours
1 month 1 week 1 day
6 months 1 month 1 week
1 year 6 months 4 months
Figure 7: See the caption for Figure 5. The weight fraction of drug here is 40%.
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T = 60◦C T = 75◦ C T = 90◦C
1 month 2 weeks 2 weeks
2 months 23 days 23 days
4 months 1 month 1 month
9 months 2 months 2 months
1 year 9 months 9 months
Figure 8: See the caption for Figure 5. The weight fraction of drug here is 20%.
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decreasing weight fractions of drug correspond to increasing weight fractions of polymer
since the system is binary. In the figures, warm colours correspond to drug-rich domains
while cooler colours correspond to polymer-rich domains. In a given figure, each column
corresponds to a given temperature as labelled, and reading a column from top to bottom cor-
responds to increasing time for the dispersion for the given temperature. We have chosen here
not to use the same times for the different temperatures since the rate at which a dispersion
evolves depends on temperature.
All of the numerical regimes explored in the current study are for the unstable case, but this
is realistic since real solid dispersions are typically unstable. This does not imply that these
dispersions are worthless since the phase separation may occur over such long timescales that
they may be considered stable for practical purposes. However, the temperatures we have
chosen for the numerical simulations here are much higher than typical storage temperatures,
and correspond to accelerated conditions. In a future study, we shall present a detailed numer-
ical investigation for a selection of dry binary solid dispersion systems for realistic storage
temperatures using our newly developed models.
We now highlight some notable features of the numerical simulations.
• Two phases eventually emerge. The numerical results show that all of the systems even-
tually evolve into two distinct phases, characterized by deep blue domains (polymer-
rich) and deep red domains (drug-rich).
• Ostwald ripening/coarsening. Another notable feature in many of the numerical illus-
trations is the formation of polymer droplets (blue discs) in the dispersion, followed by
a subsequent growth in their size; see, for example, the third column in Figure 5. This is
a well-known and common phenomenon in multicomponent solid systems, and is often
referred to as Ostwald ripening or coarsening [30]. We also note the general trend that
dispersions at higher temperature tend to be coarser.
• Phase inversion. The system exhibits the phase inversion phenomenon as the polymer
content increases. To see this, consider the panels in Figure 5. These correspond to
the case where the polymer content is low (20% by weight), and we see the emergence
of polymer droplets in drug-dominated domains. Compare these with the panels in
the third column of Figure 8. These correspond to the case where where the polymer
content is high (80% by weight), and we see the emergence of drug droplets in polymer-
rich domains, the reverse of the low polymer content case.
• Polymer strings and droplet-to-string transitions. We note the formation of polymer
strings in some of the panels; see the first and second columns of Figure 8 for examples.
The central column in Figure 8 is of particular interest since the behaviour exhibited here
is an example of a droplet-to-string transition [26]. In this droplet-to-string transition,
drug droplets coalesce to form long drug-rich strings. In the panel for 23 days, we
observe that drug droplets are in the process of chaining [26].
• The formula (45) for the timescale for phase separation. The detailed numerical results
here enable us to test the utility of our simple formula (45) for the timescale for phase
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separation. Consider, for example, the panel corresponding to 1 day in the third column
of Figure 5. Here we see that polymer droplets with characteristic lengthscale of l ≈ 0.3
mm have formed. Our formula (45) predicts that such droplets should form over a
timescale dictated by
τ ≈ (0.3)
2mm2
|D˜eff(φd = 0.8006)|
≈ 11 hours
which is consistent with the time t = 1 day for the panel since 1 day ≈ 2τ . It should be
emphasized that τ does not predict the time for the droplets to form, but rather estimates
the timescale over which such droplets form.
5 Conclusions
Solid dispersions have been the subject of intensive research in recent years because of their
potential to improve the solubility of drugs, and numerous excellent studies have been pub-
lished. However, detailed theoretical studies considering the non-equilibrium behaviour of
solid dispersions are lacking. Hence, in this study we have developed a general diffusion
model for a dissolving solid dispersion. We then considered the particular case of a binary
system modelling a solid dispersion in storage, and developed a formula for the effective dif-
fusion coefficient of the drug. We then specialized further to the case of a Flory-Huggins
statistical model. Within the context of this theory, we make the following predictions, some
of which should be testable experimentally:
1. A solid dispersion can always be made stable by choosing a sufficiently low drug load-
ing; see Figure 3 (a).
2. For unstable regimes, the relationship between the local drug volume fraction φd and the
rate of phase separation is not obvious; see Figure 3 (a). There is in fact a well-defined
value of φd that corresponds to the most rapid rate of phase separation, with the rate
decreasing for values of φd either side of this value.
3. For unstable regimes, the rate of phase separation increases with increasing polymer
chain length m; see Figure 3 (a).
4. Dispersions become more unstable with increasing value of the Flory-Huggins interac-
tion parameter χdp; see Figure 3 (b).
5. Binary drug/polymer systems are capable of exhibiting a rich set of dynamical be-
haviours. In the numerical simulations performed in the current study, we observed the
formation of polymer droplets and strings, the phase inversion phenomenon, Ostwald
ripening, and droplet-to-string transitions.
There is ample scope for extending the modelling work presented in the current study. One
limitation of the binary model considered here is that it assumes that the polymer is perfectly
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dry. However, if the dispersions are stored in humid conditions, this is not a good assumption
since even small amounts of moisture in the dispersion may significantly affect the mobility
of the drug. Another avenue for extending the modelling work developed here is to use statis-
tical models that capture more of the detail of the drug-polymer interaction in the dispersion;
see, for example, SAFT models [23]. Finally, the we have only considered the storage prob-
lem here, and have not addressed the dissolution behaviour at all. The dissolution of solid
dispersions is at best partially understood, and there are many open issues that mathematical
modelling may help resolve.
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